TCA
RNTX

Taconic Capital Advisors’s Rein Therapeutics RNTX Stock Holding History

Taconic Capital Advisors’s Portfolio RNTX Stock Details RNTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q3 		– Sell
-6,750
Closed -$35K – 684
2022
Q2 		$35K Hold
6,750
– – ﹤0.01% 533
2022
Q1 		$69K Hold
6,750
– – ﹤0.01% 525
2021
Q4 		$76K Hold
6,750
– – ﹤0.01% 479
2021
Q3 		$138K Hold
6,750
– – ﹤0.01% 353
2021
Q2 		$169K Hold
6,750
– – ﹤0.01% 373
2021
Q1 		$193K Buy
+6,750
New +$231K 0.01% 319

Other funds holding RNTX

AIM
Alerce Investment Management Chicago, Illinois $56.8M AUM 31.17% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
William Blair & Company
William Blair & Company Chicago, Illinois $34.9B AUM 18.88% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
KL
KCK Ltd Hamilton, Bermuda $15.1M AUM 30.14% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Envestnet Asset Management
Envestnet Asset Management Chicago, Illinois $374B AUM 17.66% 1-Year Est. Return
PAM
PVG Asset Management Golden, Colorado $173M AUM 64.51% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Taconic Capital Advisors's RNTX Position: Q3 2022 in Review

Taconic Capital Advisors sold out of Rein Therapeutics (RNTX) in Q3 2022, closing a stake of 6,750 shares — an estimated $35K sold.

Taconic Capital Advisors first reported a position in RNTX in Q1 2021 and held it in 6 quarters. The position peaked at $193K in Q1 2021. 33 funds tracked by Wall St. Rank hold RNTX as of Q3 2022.

  • Taconic Capital Advisors reported no remaining Rein Therapeutics position as of Q3 2022 after selling out during the quarter.
  • Taconic Capital Advisors sold 6,750 Rein Therapeutics shares in Q3 2022, an estimated $35K.
  • Taconic Capital Advisors first reported a position in Rein Therapeutics in Q1 2021 and held it in 6 quarters.
  • Taconic Capital Advisors's Rein Therapeutics position peaked at $193K in Q1 2021.
  • 33 funds tracked by Wall St. Rank held Rein Therapeutics as of Q3 2022.

Based on Taconic Capital Advisors's 13F filing for Q3 2022, filed 14 Nov 2022.